Mitochondrial Peptide · Research Grade · Human Trials

SS-31 (Elamipretide): The Mitochondrial Peptide

📄 3 PubMed citations

Last updated: October 3, 2026

SS-31 (elamipretide) is a mitochondria-targeted peptide. Under the name elamipretide it has been tested in human trials and received FDA accelerated approval for Barth syndrome in 2025 (FDA announcement), and its proposed mechanism is unusual among peptides: binding and protecting cardiolipin in the inner mitochondrial membrane.

2025
FDA Accelerated Approval
Barth syndrome (Forzinity)
1000x
Inner-Membrane Concentration
Measured for this peptide class in cell studies (Zhao 2004, PMID 15178689)
4
Amino Acids
Tetrapeptide — D-Arg-dmtTyr-Lys-Phe-NH2

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

How SS-31 Targets Mitochondria

SS-31 does more than reach mitochondria: it concentrates specifically in the inner mitochondrial membrane (IMM), where cardiolipin lives. Its activity is thought to depend on this targeting.

🎯
Cardiolipin Stabilization

Cardiolipin is a phospholipid of the inner mitochondrial membrane that binds cytochrome c and is required for cristae formation. Its peroxidation damages mitochondria. In lab studies, SS-31 bound cardiolipin with high affinity and inhibited the cytochrome c peroxidase activity that oxidizes it (Birk et al., 2013, PMID 23813215).

⚡
Electron Transport Chain Support

The electron transport chain (ETC) is the ATP-producing machinery, and electron leak from damaged ETC complexes creates superoxide. By protecting cardiolipin, SS-31 is proposed to support ETC efficiency and reduce electron leak. This is a hypothesis from lab and animal work, not an effect measured in human trials.

🛡️
Reactive Oxygen Species Reduction

In this peptide family, the dimethyltyrosine residue provides ROS-scavenging properties (PMID 15178689), but SS-31's main proposed action is upstream: reducing electron leak from damaged ETC complexes, so cells produce less superoxide in the first place.

🏗️
Cristae Architecture Preservation

Mitochondrial cristae (the inner membrane folds) are where ATP synthesis happens. In rats, SS-31 pretreatment protected cristae membranes and prevented mitochondrial swelling during kidney ischemia (PMID 23813215). Whether this happens in human tissue is not established.

What the Research Shows

SS-31 has been studied across multiple disease areas. Evidence strength varies — human trials exist for heart failure, mitochondrial myopathy, Barth syndrome and dry AMD; the remaining areas below rest on lab and animal studies.

Heart Failure
Phase 2 human trial (PROGRESS-HF, HFrEF) — primary endpoint not met
Human Data
Kidney Ischemia-Reperfusion Injury
Rat studies — SS-31 sped ATP recovery and reduced acute kidney injury after renal ischemia (PMID 23813215)
Preclinical
Skeletal Muscle Aging / Sarcopenia
Studied in aged-animal models of muscle mitochondrial function
Preclinical
Retinal Degeneration
Studied in retinal degeneration models; ReCLAIM-2, a randomized Phase 2 trial in 176 patients with dry AMD and geographic atrophy, did not meet its primary endpoints, though elamipretide was associated with slower ellipsoid zone degradation/loss, a predefined additional endpoint reported with nominal P values (PMID 39605874)
Preclinical + Phase 2
Neurodegeneration (Alzheimer's, Parkinson's)
Cell and animal models of mitochondrial dysfunction
Early Preclinical
Anti-Aging / Longevity
Aged-mouse studies of cardiac and muscle function — not lifespan
Exploratory
💬 Community Reports (Anecdotal)

Beyond the clinical trials, some athletes self-experimenting with SS-31 describe a "lights coming on" feeling — noticeably faster recovery between hard training sessions. These are uncontrolled accounts from anonymous forum users, not evidence, and none of the human trials summarized here tested athletic performance or recovery. Treat them as unverified claims.

Human Trials: What We Know

SS-31/elamipretide has been tested in randomized human trials, with mixed results. Here's what the data showed.

🫀
PROGRESS-HF (Heart Failure)

Phase 2 randomized trial in 71 patients with heart failure with reduced ejection fraction. Elamipretide 4 mg or 40 mg once daily by subcutaneous injection for 28 days was well tolerated but did not improve left ventricular end-systolic volume versus placebo (Butler et al., 2020, J Card Fail).

📊
MMPOWER-3 (Mitochondrial Myopathy)

Phase 3 randomized trial in 218 adults with primary mitochondrial myopathy, 40 mg/day subcutaneous for 24 weeks. It did not meet its primary endpoints, the 6-minute walk test and a fatigue score (Karaa et al., 2023, Neurology).

🧬
Barth Syndrome Studies

In the TAZPOWER trial (12 patients with Barth syndrome, 40 mg/day), the randomized crossover phase missed both primary endpoints; in the open-label extension, 6-minute walk distance and fatigue improved, sustained through 168 weeks (Thompson et al., 2021 and 2024, Genet Med). On September 19, 2025 the FDA granted Forzinity (elamipretide) accelerated approval as the first treatment for Barth syndrome, in patients weighing at least 30 kg, based on improved strength of the knee-extensor muscle; a confirmatory trial is required (FDA press announcement).

⚠️
What Phase 2 Means (and Doesn't)

Phase 2 trials gather early safety data and look for preliminary efficacy signals — they're not definitive proof. Elamipretide's results are mixed: negative primary endpoints in heart failure and mitochondrial myopathy trials, and an accelerated approval only in Barth syndrome. The compound is real and its proposed mechanism has lab and animal support — but "showed results in Phase 2" is not the same as "proven to work."

Research Dosing Guide

Oral bioavailability has not been established; the human trials below used subcutaneous injection. The only doses with human data are the trial doses below.

Context Dose Route Frequency
Human trials (TAZPOWER, MMPOWER-3, PROGRESS-HF) 40 mg/day (PROGRESS-HF also tested 4 mg) SubQ injection Once daily
💡 Peptide Quality Matters

SS-31 is a small tetrapeptide — relatively easy to synthesize but easy to fake with fragments or impurities. Always verify purity from vendor COAs. For research-grade SS-31, ask for HPLC purity and mass-spec results on the certificate of analysis.

Side Effects & Safety

In the published trials summarized here, injection-site reactions were the most commonly reported adverse events. In ReCLAIM-2, adverse events were reported in 86% of those receiving elamipretide and 71% of the placebo group (PMID 39605874). The largest trials described here enrolled 176 patients for 48 weeks (ReCLAIM-2) and 218 patients for 24 weeks (MMPOWER-3), which is too few and too short to establish rarer or long-term effects.

✅
Known Safety (From Trials)

Adverse events were more frequent with elamipretide than placebo in ReCLAIM-2 (86% vs 71%), most commonly injection-site reactions. The trials summarized here enrolled 12 (TAZPOWER) to 218 (MMPOWER-3) patients, with randomized treatment periods such as 28 days (PROGRESS-HF) and 48 weeks (ReCLAIM-2) — not enough to rule out less common or long-term harms.

💉
Injection Site Reactions

Injection-site reactions were the most common adverse events in the TAZPOWER extension study. Rotating injection sites is a standard way to limit them.

🔬
Drug Interactions: Not Established

Formal drug-interaction data are not covered in the trial reports summarized here. Anyone on cardiac or other prescription medications should treat interactions as unknown.

❓
Unknown Risks

The longest follow-up comes from small Barth syndrome extension studies (8 patients reached 168 weeks); among randomized trials described here, ReCLAIM-2 ran 48 weeks in 176 patients. Effects in healthy individuals (vs. disease populations) are unknown. The trials enrolled sick patients — effects in healthy people optimizing mitochondrial function are extrapolated, not directly studied. This is the standard caveat for all research peptides.

Side Effects Frequency

Published trial reports name injection-site reactions as the most common adverse events. Apart from ReCLAIM-2's overall adverse-event rates (86% elamipretide vs 71% placebo, noted above), we do not list frequency percentages because the trials summarized here report them in different ways.

Key Takeaways

What We Know
  • Elamipretide (Forzinity) received FDA accelerated approval for Barth syndrome, in patients weighing at least 30 kg, on September 19, 2025 (FDA)
  • Injection-site reactions were the most common adverse events in published trials; in ReCLAIM-2, adverse events were reported in 86% on elamipretide vs 71% on placebo
  • Proposed mechanism: binds cardiolipin and protects it from peroxidation in lab and animal studies (PMID 23813215)
  • Peptides of this class concentrated about 1000-fold in the inner mitochondrial membrane in cell studies (Zhao et al., 2004, PMID 15178689)
  • Injection-site reactions were the most common adverse events in trials
What We Don't Know
  • Phase 3 trial in mitochondrial myopathy (MMPOWER-3) missed its primary endpoints
  • Long-term safety data come mainly from small Barth syndrome studies
  • Effects in healthy individuals vs. disease populations are extrapolated
  • Optimal dosing for longevity or performance enhancement unknown
  • Oral bioavailability is not established — trials used subcutaneous injection
⚠️ Research Purposes Only

Elamipretide is FDA-approved (as Forzinity, accelerated approval, September 2025; FDA announcement) only for Barth syndrome; SS-31 sold as a research compound is not an approved drug. This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified physician before using any research compound. HighPeptides makes no claims about efficacy or safety for personal use.

Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) The Peptide Buyer’s Playbook ($19) All ebooks & guides →
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.